Publications
Spotlight Publication
Balstilimab (PD-1 Antagonist), Botensilimab (Fc-Enhanced CTLA-4 Antagonist)
European Society for Medical Oncology (ESMO) GI
Jun 28
- Jul 1, 2023
Results from an expanded phase 1 trial of botensilimab, a multifunctional anti-CTLA-4, plus balstilimab(anti-PD-1) for metastatic heavily pretreated microsatellite stable colorectal cancer
Bullock, et al.
Filter by
Zalifrelimab (CTLA-4 Antagonist)
European Society for Medical Oncology (ESMO) Virtual
Sep 16
- Sep 21, 2021
Balstilimab (anti-PD-1) in Combination with Zalifrelimab (anti-CTLA-4): Final Results from a Phase 2 Study in Patients (pts) with Recurrent/metastatic (R/M) Cervical Cancer (CC).
O’Malley, et al.
Balstilimab (PD-1 Antagonist)
European Society for Medical Oncology (ESMO) Virtual
Sep 16
- Sep 21, 2021
Balstilimab (anti-PD-1) in Combination with Zalifrelimab (anti-CTLA-4): Final Results from a Phase 2 Study in Patients (pts) with Recurrent/metastatic (R/M) Cervical Cancer (CC).
O’Malley, et al.
Zalifrelimab (CTLA-4 Antagonist)
European Society for Medical Oncology (ESMO) Virtual
Sep 16
- Sep 21, 2021
Balstilimab Alone or in Combination with Zalifrelimab as Second-line Treatment for Patients with Previously Treated Recurrent/metastatic Cervical Cancer: a Randomized, Placebo-Controlled Phase II Trial (RaPiDS/GOG-3028).
Randall, et al.
Balstilimab (PD-1 Antagonist)
Gynecologic Oncology
Aug 25, 2021
Phase II study of the safety and efficacy of the anti-PD-1 antibody balstilimab in patients with recurrent and/or metastatic cervical cancer.
O’Malley, et al.
Balstilimab (PD-1 Antagonist), Zalifrelimab (CTLA-4 Antagonist)
Future Oncology
Aug 19, 2021
RaPiDS (GOG-3028): randomized Phase II study of balstilimab alone or in combination with zalifrelimab in cervical cancer.
O’Malley, et al.
Balstilimab (PD-1 Antagonist)
American Society of Clinical Oncology (ASCO)
Jun 3
- Jun 7, 2021
Differentiated Activity Profile for the PD-1 Inhibitor Balstilimab.
C.Joyce, et al.